Ossiam Sells 549 Shares of Edwards Lifesciences Co. (NYSE:EW)

by · The Cerbat Gem

Ossiam decreased its position in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 1.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 33,524 shares of the medical research company’s stock after selling 549 shares during the quarter. Ossiam’s holdings in Edwards Lifesciences were worth $2,482,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. lifted its holdings in Edwards Lifesciences by 2.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after buying an additional 273 shares during the period. Nordea Investment Management AB raised its position in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after acquiring an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its stake in shares of Edwards Lifesciences by 6.7% in the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares during the period. Sivik Global Healthcare LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $3,702,000. Finally, Avanza Fonder AB bought a new position in shares of Edwards Lifesciences in the 4th quarter worth $4,845,000. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 400 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares of the company’s stock, valued at approximately $1,569,414.24. This represents a 1.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company’s stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,853 shares of company stock worth $5,163,062 in the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their target price for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Piper Sandler increased their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Truist Financial decreased their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a report on Friday, April 11th. Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Finally, Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $78.55.

Get Our Latest Stock Analysis on Edwards Lifesciences

Edwards Lifesciences Stock Up 0.5 %

Edwards Lifesciences stock opened at $71.56 on Monday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25. The company has a fifty day simple moving average of $71.31 and a 200 day simple moving average of $70.92. The company has a market cap of $42.07 billion, a P/E ratio of 10.27, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Articles